| Name | Notoginsenoside Ft1 |
| Description | Notoginsenoside Ft1 is a saponin originally isolated from P. notoginseng with diverse biological activities |
| Kinase Assay | Platelet aggregation was analysed using a platelet aggregometer. Prothrombin time, activated partial thromboplastin time and thrombin time were measured using a blood coagulation analyser, which was further corroborated with bleeding time and thrombotic assays[2]. |
| In vitro | Notoginsenoside Ft1 (Ft1) is a novel stimulator of angiogenesis. Ft1 induces proliferation, migration, and tube formation in cultured human umbilical vein endothelial cells (HUVECs). Ft1 increases translocalization of hypoxia-inducible factor-1α (HIF-1α) from cytoplasm to nuclei, where it binds to the vascular endothelial growth factor (VEGF) promoter, increasing the expression of VEGF mRNA and the subsequent secretion of the growth factor. Ft1 induces the activation of PI3K/AKT and Raf/MEK/ERK signaling pathways. Pharmacological inhibition with LY294002, wortmanin or PD98059 reduces Ft1-induced angiogenesis, indicating the important role played by these pathways. In addition, Ft1 induces phosphorylation of the mammalian target of rapamycin (mTOR), and siRNA-mediated mTOR knockdown decreases tube formation, proliferation, transport of HIF-1α into nuclei and VEGF mRNA expression in response to Ft1[1].Among the saponins examined, Notoginsenoside Ft1(Ft1) was the most potent procoagulant and induced dose-dependent platelet aggregation. Ft1 reduced plasma coagulation indexes, decreased tail bleeding time and increased thrombogenesis. Moreover, it potentiated ADP-induced platelet aggregation and increased cytosolic Ca(2+) accumulation, effects that were attenuated by clopidogrel[2]. |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 25 mg/mL (27.26 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (2.18 mM), Sonication is recommended.
|
| Keywords | Notoginsenoside Ft-1 | Notoginsenoside Ft1 | Notoginsenoside Ft 1 | Inhibitor | inhibit | HIFProlylHydroxylase | HIF/HIFProlylHydroxylase | HIF/HIF Prolyl-Hydroxylase | HIF/HIF ProlylHydroxylase | HIF Prolyl-Hydroxylase | HIF ProlylHydroxylase | HIF |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Metronidazole | Citric Acid Triammonium | Tributyrin | L-Methionine | Sodium citrate | Cystamine dihydrochloride | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Glycometabolism Compound Library | Terpene Natural Product Library | Bioactive Compound Library | Traditional Chinese Medicine Monomer Library | Selected Plant-Sourced Compound Library | Miao medicine Compound Library | Saccharide and Glycoside Natural Product Library | Natural Product Library | Natural Product Library for HTS | PBCRBS Traditional Chinese Medicine Compound Library | Bioactive Compounds Library Max |
United States
